ZERO2IPO (01945) released its interim results, with shareholder profit amounting to 15.103 million yuan, achieving a turnaround from loss to profit year-on-year.
Qingke Holdings (01945) announced its mid-year results for 2026, reporting revenue of 71.029 million yuan, an increase of 27.24% year-on-year; the profit attributable to shareholders was 15.103 million yuan, compared to a loss of 15.312 million yuan in the same period last year; earnings per share were 0.05 yuan.
ZERO2IPO (01945) has released its mid-term results for 2026, reporting revenue of 71.029 million yuan, a year-on-year increase of 27.24%. The profit attributable to shareholders reached 15.103 million yuan, compared to a loss of 15.312 million yuan in the same period last year; earnings per share stood at 0.05 yuan.
The announcement stated that the increase in revenue was primarily due to the growth in the company's investment banking business, benefiting from the realization of previously reserved projects during the current period, as well as a year-on-year increase in marketing service revenue, mainly driven by rising demand for advertising services.
The company's gross profit rose by 252.2% from 6.9 million yuan in the six months ended June 30, 2025, to 24.3 million yuan in the same period of 2026. The company's gross profit margin increased from 12.4% in the six months ended June 30, 2025, to 34.2% in the same period of 2026.
Related Articles

CH INNOVATION (01217) has a net asset value per share of approximately HKD 0.044 at the end of July.

HONGHUA GROUP (00196): Wang Xu resigns as executive director

AKESO (09926): The application for the third indication of Yidafang (Ivosidenib, PD-1/VEGF) has been approved by the National Medical Products Administration for first-line treatment of SQ-NSCLC.
CH INNOVATION (01217) has a net asset value per share of approximately HKD 0.044 at the end of July.

HONGHUA GROUP (00196): Wang Xu resigns as executive director

AKESO (09926): The application for the third indication of Yidafang (Ivosidenib, PD-1/VEGF) has been approved by the National Medical Products Administration for first-line treatment of SQ-NSCLC.

RECOMMEND





